Lilly licenses Hanmi's Btk inhibitor

Eli Lilly and Co. (NYSE:LLY) obtained exclusive, worldwide rights outside of certain Asian territories to HM71224, an oral Bruton's tyrosine kinase (Btk) inhibitor from Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940). The companies plan to evaluate the compound in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), lupus nephritis, Sjogren's syndrome and related diseases.

Lilly will pay Hanmi $50 million up front for global rights excluding China, Hong Kong, Taiwan and Korea. Hanmi is eligible for $640 million in milestones, plus tiered, double-digit royalties. Lilly will lead development, regulatory, manufacturing and commercial activities in its territories. ...